Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571025 · ClinicalTrials.gov registry record · NA
Risk Evaluation and Education for Alzheimer's Disease
A NA study, sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- NA
- Development phase
- 301
- Enrollment target
NCT00571025 is a NA study that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 301 participants.
The verdict
NCT00571025, a NA study, has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- NA
- Development phase
- 301 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the characteristics of those who obtain genetic susceptibility testing for Alzheimer's disease with APOE disclosure and to study the psychological and behavioral consequences of providing this information.
Interventions
- BEHAVIORAL APOE Disclosure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2000-08 |
| Est. Completion | 2004-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571025
The ClinicalTrials.gov registry entry for NCT00571025 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Human Genome Research Institute (NHGRI), which has 185 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which APOE Disclosure is the first listed.
NCT00571025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571025 about?
NCT00571025 is a clinical study titled "Risk Evaluation and Education for Alzheimer's Disease". The purpose of this study is to determine the characteristics of those who obtain genetic susceptibility testing for Alzheimer's disease with APOE disclosure and to study the psychological and behavioral consequences of providing this information.
What is the current status of trial NCT00571025?
This trial is currently completed. It is a NA study. The enrollment target is 301 participants. The study started on 2000-08. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00571025?
The interventions under investigation include: APOE Disclosure (BEHAVIORAL).
Who is sponsoring clinical trial NCT00571025?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.